Skip to main content

BASES ESTRUCTURALES DE LA GENERACION, ACTIVIDAD E INHIBICION DE LA TROMBINA

SAF2010-15668

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural and functional analysis of APOA5 mutations identifi ed in patients with severe hypertriglyceridemia

  • Mendoza-Barberá, Elena|||0000-0002-6374-4125
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Nilsson, Stefan K.
  • Lookene, Aivar
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Roig, Rosa|||0000-0002-3055-9791
  • Lechuga-Sancho, Alfonso M.
  • Sloan, John H.
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
During the diagnosis of three unrelated patients with severe hypertriglyceridemia, three APOA5 mutations [p.(Ser232-Leu235)del, p.Leu253Pro, and p.Asp332ValfsX4] were found without evidence of concomitant LPL, APOC2, or GPIHBP1 mutations. The molecular mechanisms by which APOA5 mutations result in severe hypertriglyceridemia remain poorly understood, and the functional impairment/s induced by these specifi c mutations was not obvious. Therefore, we performed a thorough structural and functional analysis that included follow-up of patients and their closest relatives, measurement of apoA-V serum concentrations, and sequencing of the APOA5 gene in 200 nonhyperlipidemic controls. Further, we cloned, overexpressed, and purifi ed both wild-type and mutant apoA-V variants and characterized their capacity to activate LPL. The interactions of recombinant wild-type and mutated apoA-V variants with liposomes of different composition, heparin, LRP1, sortilin, and SorLA/LR11 were also analyzed. Finally, to explore the possible structural consequences of these mutations, we developed a three-dimensional model of full-length, lipid-free human apoA-V. A complex, wide array of impairments was found in each of the three mutants, suggesting that the specifi c residues affected are critical structural determinants for apoA-V function in lipoprotein metabolism and, therefore, that these APOA5 mutations are a direct cause of hypertriglyceridemia.Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc..
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

K domain CR9 of low density lipoprotein (LDL) receptor-related protein 1 (LRP1) is critical for aggregated LDL-induced foam cell formation from human vascular smooth muscle cells

  • Costales, Paula
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Castellano, José
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Corral-Rodríguez, Maria Ángeles|||0000-0002-7875-1694
  • Nasarre, Laura
  • Badimon, Lina|||0000-0002-9162-2459
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low density lipoprotein receptor-related protein (LRP1) mediates the internalization of aggregated LDL (AgLDL), which in turn increases the expression of LRP1 in human vascular smooth muscle cells (hVSMCs). This positive feedback mechanism is thus highly efficient to promote the formation of hVSMC foam cells, a crucial vascular component determining the susceptibility of atherosclerotic plaque to rupture. Here we have determined the LRP1 domains involved in AgLDL recognition with the aim of specifically blocking AgLDL internalization in hVSMCs. The capacity of fluorescently labeled AgLDL to bind to functional LRP1 clusters was tested in a receptor-ligand fluorometric assay made by immobilizing soluble LRP1 "minireceptors"(sLRP1-II, sLRP1-III, and sLRP1-IV) recombinantly expressed in CHO cells. This assay showed that AgLDL binds to cluster II. We predicted three well exposed and potentially immunogenic peptides in the CR7-CR9 domains of this cluster (termed P1 (Cys-Glu), P2 (Asp-Cys), and P3 (Gly-Cys)). AgLDL, but not native LDL, bound specifically and tightly to P3-coated wells. Rabbit polyclonal antibodies raised against P3 prevented AgLDL uptake by hVSMCs and were almost twice as effective as anti-P1 and anti-P2 Abs in reducing intracellular cholesteryl ester accumulation. Moreover, anti-P3 Abs efficiently prevented AgLDL-induced LRP1 up-regulation and counteracted the down-regulatory effect of AgLDL on hVSMC migration. In conclusion, domain CR9 appears to be critical for LRP1-mediated AgLDL binding and internalization in hVSMCs. Our results open new avenues for an innovative anti-VSMC foam cell-based strategy for the treatment of vascular lipid deposition in atherosclerosis.